Thursday, October 24, 2013
This week in techniques
Publication and contact
Algorithm to predict risk
of developing neutralizing antibodies to factor
A computational algorithm
to predict the risk of developing factor VIII-neutralizing inhibitory
antibodies could help guide the treatment of patients with hemophilia A.
Sequencing and gene expression analysis of samples from patients who have
hemophilia A caused by intron 22 inverted (I22I) factor VIII found
that the entire factor VIII protein was expressed as two polypeptides, which
explains why patients carrying this inversion have decreased risk of
developing inhibitory antibodies against factor VIII replacement therapy
compared with patients who have factor VIII deletions. A computational
algorithm that analyzes the affinity of major
histocompatibility complex class II (MHCII)
for foreign peptides was developed. The algorithm was used to predict whether
differences between recombinant factor VIII products and patient-encoded I22I
factor VIII would lead to inhibitor development. Next steps include applying
this algorithm to analyze the immune response to other foreign peptides.
Published online Oct. 24, 2013
Patent applications filed
covering the development of personalized factor VIII replacement therapies;
licensed to Haplomics
Pandey, G.S. et al. Nat.
Med.; published online Sept. 15, 2013;
Contact: Zuben E. Sauna, Food and Drug Administration,
Contact: Tom E. Howard, VA Greater Los Angeles Healthcare
System, Los Angeles, Calif.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]